Ostke SPPI aktsiat(kullalt pohjusi....)!
Kommentaari jätmiseks loo konto või logi sisse
-
1) New management in place with proven track record of bringing several anti cancer drugs to commercial markets.
2) $50 mln deal with GPC Biotech for Satraplatin that is a phase 3 drug
3) Insiders buying heavily
4) Several drugs in pipeline with billions of dollars potential.
5) Float is tiny - under 3 mln shares
6) Market capital is very low - under $4 mln
7) Float mostly in hands of investors in for long term
8) Entry into Generic drugs business which has US market potential of north of $15 bln/yr
9) Attractive buyout candidate
10) Strategic investment & deal with India's leading Pharmaceuticals company JB Pharma & Chem
11) Company has spend over $150 millions in research over the last 10+ years -
kui ta tõuseks kahe nädalaga 7 peale, siis võibolla ostaks
-
WWTR - praegu on 0.25. kaks aastat järjest on olnud 1,0 aprillis. kas ka seekord. kas ma olen liiga naiivne
-
võibolla osta täna, lootes homsele põrkele?
-
SPPI edasine noteerimine NASDAQil on küsimärk.Küllaldane põhjus mitte osta:(
-
Täna +46%
-
2) $50 mln deal with GPC Biotech for Satraplatin that is a phase 3 drug
.... osta siis parem juba GPC Biotechi, kellel on võimalus päris mõjukaks ravimifirmaks kujuneda.
